Senescent Immune Cells Impair Osteoblast Carboxylation and Mineralization via SASP-Induced Suppression of γ-Glutamyl Carboxylase

Amara Afriyie· Mar 21, 2026

$Mechanism: Senescent immune cells secrete SASP factors (TNF-α, ROS) that inhibit osteoblast GGCX activity via miRNA-122 and vitamin K oxidation, impairing osteocalcin carboxylation and bone mineralization. Readout: Readout: Senolytic treatment reduces noncarboxylated osteocalcin ratios, improves GGCX activity, and increases bone strength/fracture resistance.$

Hypothesis

We hypothesize that chronic exposure of aged osteoblasts to senescence-associated secretory phenotype (SASP) factors from immune cells directly inhibits the vitamin K‑dependent γ‑glutamyl carboxylase (GGCX) activity, leading to elevated noncarboxylated osteocalcin and defective hydroxyapatite nucleation.

Rationale

Aged humans show increased serum noncarboxylated osteocalcin (1.59 ± 1.1 ng/ml) versus premenopausal levels (0.65 ± 0.5 ng/ml) despite adequate vitamin K, indicating a block in the carboxylation step {[https://pubmed.ncbi.nlm.nih.gov/1666807/]}
Carboxylated osteocalcin binds hydroxyapatite with high affinity; its deficiency reduces crystal nucleation and promotes larger, brittle crystals {[https://pubmed.ncbi.nlm.nih.gov/11368299/]; [https://repository.lsu.edu/cgi/viewcontent.cgi?article=3338&context=gradschool_theses]}
Osteoblasts from aged mice exhibit reduced expression of bone matrix proteins and this phenotype is retained in stromal stem cells, pointing to an upstream dysregulation {[https://pubmed.ncbi.nlm.nih.gov/37519232/]}
Senescent immune cells accumulate with age and secrete a SASP rich in IL‑6, TNF‑α, ROS, and prostaglandins that can alter enzyme activity in neighboring cells {[https://pubmed.ncbi.nlm.nih.gov/29563310/]}

Mechanistic Model

SASP cytokines (e.g., TNF‑α) activate NF‑κB signaling in osteoblasts, which upregulates expression of microRNA‑122 that directly represses GGCX translation.
Oxidative metabolites from SASP (e.g., H₂O₂) oxidize the reduced vitamin K hydroquinone cofactor, rendering it unavailable for γ‑glutamyl carboxylation.
Combined, these actions lower the ratio of carboxylated to noncarboxylated osteocalcin, impairing its ability to nucleate hydroxyapatite and shifting crystal growth toward larger, less perfect aggregates.

Testable Predictions

Prediction 1: In vitro treatment of young human osteoblasts with conditioned medium from senescent macrophages will decrease GGCX activity and increase the noncarboxylated/total osteocalcin ratio.
Prediction 2: Neutralizing TNF‑α or IL‑6 in the conditioned medium will rescue GGCX activity and restore normal osteocalcin carboxylation.
Prediction 3: Aged mice treated systemically with a senolytic that eliminates p16^INK4a^‑positive immune cells will show increased serum carboxylated osteocalcin, smaller hydroxyapatite crystals (by nanoscale XRD), and improved bone biomechanical strength.

Experimental Design

In vitro: Isolate peritoneal macrophages from young and old mice, induce senescence with etoposide, collect conditioned medium, apply to MC3T3‑E1 cells, measure GGCX activity (γ‑glutamyl carboxylase assay), osteocalcin carboxylation (ELISA for carboxylated vs total), and hydroxyapatite nucleation (Alizarin Red S quantification and TEM crystal size).
In vivo: Use p16‑3MR mice to ablate senescent immune cells via ganciclovir; longitudinally monitor serum osteocalcin forms, bone mineral density (DXA), bone quality (micro‑Finite Element analysis), and fracture resistance.

Falsifiability

If senescent immune‑cell conditioned medium does not alter GGCX activity or osteocalcin carboxylation, or if senolytic clearance of immune senescence fails to improve osteocalcin carboxylation and bone quality despite reducing other SASP markers, the hypothesis would be falsified.

Hypothesis

Rationale

Aged humans show increased serum noncarboxylated osteocalcin (1.59 ± 1.1 ng/ml) versus premenopausal levels (0.65 ± 0.5 ng/ml) despite adequate vitamin K, indicating a block in the carboxylation step {[https://pubmed.ncbi.nlm.nih.gov/1666807/]}

Carboxylated osteocalcin binds hydroxyapatite with high affinity; its deficiency reduces crystal nucleation and promotes larger, brittle crystals {[https://pubmed.ncbi.nlm.nih.gov/11368299/]; [https://repository.lsu.edu/cgi/viewcontent.cgi?article=3338&context=gradschool_theses]}

Osteoblasts from aged mice exhibit reduced expression of bone matrix proteins and this phenotype is retained in stromal stem cells, pointing to an upstream dysregulation {[https://pubmed.ncbi.nlm.nih.gov/37519232/]}

Senescent immune cells accumulate with age and secrete a SASP rich in IL‑6, TNF‑α, ROS, and prostaglandins that can alter enzyme activity in neighboring cells {[https://pubmed.ncbi.nlm.nih.gov/29563310/]}

Mechanistic Model

SASP cytokines (e.g., TNF‑α) activate NF‑κB signaling in osteoblasts, which upregulates expression of microRNA‑122 that directly represses GGCX translation.

Oxidative metabolites from SASP (e.g., H₂O₂) oxidize the reduced vitamin K hydroquinone cofactor, rendering it unavailable for γ‑glutamyl carboxylation.

Combined, these actions lower the ratio of carboxylated to noncarboxylated osteocalcin, impairing its ability to nucleate hydroxyapatite and shifting crystal growth toward larger, less perfect aggregates.

Testable Predictions

Prediction 1: In vitro treatment of young human osteoblasts with conditioned medium from senescent macrophages will decrease GGCX activity and increase the noncarboxylated/total osteocalcin ratio.

Prediction 2: Neutralizing TNF‑α or IL‑6 in the conditioned medium will rescue GGCX activity and restore normal osteocalcin carboxylation.

Prediction 3: Aged mice treated systemically with a senolytic that eliminates p16^INK4a^‑positive immune cells will show increased serum carboxylated osteocalcin, smaller hydroxyapatite crystals (by nanoscale XRD), and improved bone biomechanical strength.

Experimental Design

In vitro: Isolate peritoneal macrophages from young and old mice, induce senescence with etoposide, collect conditioned medium, apply to MC3T3‑E1 cells, measure GGCX activity (γ‑glutamyl carboxylase assay), osteocalcin carboxylation (ELISA for carboxylated vs total), and hydroxyapatite nucleation (Alizarin Red S quantification and TEM crystal size).

In vivo: Use p16‑3MR mice to ablate senescent immune cells via ganciclovir; longitudinally monitor serum osteocalcin forms, bone mineral density (DXA), bone quality (micro‑Finite Element analysis), and fracture resistance.